Akebia Presents Results from INNO2VATE Global Phase 3 Program for Vadadustat at ASN Kidney Week

Akebia’s Response to COVID-19

As a member of the renal community, the health of our patients and employees is our first priority.

For patients in the U.S. taking a prescribed Akebia product, please visit or call 855-686-8601 for assistance.


Making a difference by
challenging the status quo


We are better together

A trusted leader in the renal community delivering new therapeutic options to people with kidney disease.

We are a fully integrated biopharmaceutical company. Our team works to address complications of kidney disease. We have both a commercially available medicine and a late stage oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), vadadustat, in global Phase 3 clinical development for the treatment of anemia due to CKD. Vadadustat and other HIF-PHIs are based on Nobel Prize-winning science.

Vadadustat is an investigational drug that has not been approved by the U.S. Food and Drug Administration (FDA) or any regulatory authority for use outside of Japan. Within Japan, Vadadustat is approved as a treatment for anemia due to CKD in both dialysis-dependent and non-dialysis dependent adult patients, and will be marketed by Mitsubishi Tanabe Pharma Corporation in Japan under the trade name VAFSEO™.

Be part of a passionate team working to protect the kidneys and to innovate for better lives

Nearly 37 million Americans

are currently affected by chronic kidney disease.

Chronic kidney disease is a serious and life-altering illness that is persistent, progressive, and irreversible.

Centers for Disease Control and Prevention. Chronic Kidney Disease in the United States, 2019. Available at: Accessed: September 3, 2019.


Akebia Therapeutics, Inc.
245 First Street, Suite 1400
Cambridge, MA 02142

Driving Directions

+1 617.871.2098  phone
+1 617.871.2099  fax

Contact Us